HomeBMXMF • OTCMKTS
add
BioMerieux SA
Previous close
$134.24
Year range
$100.50 - $152.00
Market cap
13.80B EUR
Avg Volume
81.00
P/E ratio
-
Dividend yield
-
Primary exchange
EPA
Market news
Financials
Income Statement
Revenue
Net income
| (EUR) | Jun 2025info | Y/Y change |
|---|---|---|
Revenue | 1.02B | 7.46% |
Operating expense | 479.10M | 23.72% |
Net income | 80.50M | -25.22% |
Net profit margin | 7.88 | -30.39% |
Earnings per share | — | — |
EBITDA | 247.30M | 23.71% |
Effective tax rate | 24.67% | — |
Balance Sheet
Total assets
Total liabilities
| (EUR) | Jun 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 380.50M | 39.79% |
Total assets | 5.37B | 0.89% |
Total liabilities | 1.43B | -0.74% |
Total equity | 3.94B | — |
Shares outstanding | 118.38M | — |
Price to book | 4.04 | — |
Return on assets | 4.86% | — |
Return on capital | 5.87% | — |
Cash Flow
Net change in cash
| (EUR) | Jun 2025info | Y/Y change |
|---|---|---|
Net income | 80.50M | -25.22% |
Cash from operations | 158.75M | 61.09% |
Cash from investing | -139.65M | -66.15% |
Cash from financing | -38.25M | 33.65% |
Net change in cash | -42.55M | -5.19% |
Free cash flow | 138.12M | 57.50% |
About
bioMérieux SA is a French multinational biotechnology company founded and headquartered in Marcy-l'Étoile, France, close to Lyon. bioMérieux is present in 44 countries and serves more than 160 countries through a large network of distributors.
bioMérieux provides diagnostic solutions which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases, cancer screening, and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products. bioMérieux is listed on the Euronext Paris stock exchange. Wikipedia
Founded
1963
Headquarters
Website
Employees
14,451
